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Background: Nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) is a well defined risk factor
for subsequent bacteremia and death in various groups of patients, but its impact on outcome in patients receiving
long-term hemodialysis (HD) is under debate.
Methods: This prospective interventional cohort study (performed 2004 to 2010) enrolled 289 HD outpatients of an
urban dialysis-unit. Nasal swab cultures for MRSA were performed in all patients upon first admission, at transfer
from another dialysis facility or readmission after hospitalisation. Nasal MRSA carriers were treated in a separate
ward and received mupirocin nasal ointment. Concomitant extra-nasal MRSA colonization was treated with 0.2%
chlorhexidine mouth rinse (throat) or octenidine dihydrochloride containing antiseptic soaps and 2% chlorhexidine
body washes (skin). Clinical data and outcome of carriers and noncarriers were systematically analyzed.
Results: The screening approach identified 34 nasal MRSA carriers (11.7%). Extra-nasal MRSA colonization was
observed in 11/34 (32%) nasal MRSA carriers. History of malignancy and an increased Charlson Comorbidity Index
were significant predictors for nasal MRSA carriers, whereas traditional risk factors for MRSA colonization or markers
of inflammation or malnutrition were not able to discriminate. Kaplan-Meier analysis demonstrated significant
survival differences between MRSA carriers and noncarriers. Mupirocin ointment persistently eliminated nasal MRSA
colonization in 26/34 (73.5%) patients. Persistent nasal MRSA carriers with failure of this eradication approach had
an extremely poor prognosis with an all-cause mortality rate >85%.
Conclusions: Nasal MRSA carriage with failure of mupirocin decolonization was associated with increased mortality
despite a lack of overt clinical signs of infection. Further studies are needed to demonstrate whether nasal MRSA
colonization represents a novel predictor of worse outcome or just another surrogate marker of the burden of
comorbid diseases leading to fatal outcome in HD patients.
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Despite great technological advances in hemodialysis
(HD) therapy mortality rates of HD patients remain un-
satisfactorily high [1]. Next to cardiovascular diseases,
infections are major causes of morbidity, hospitalization
and mortality in this population. Staphylococcus aureus
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reproduction in any medium, provided the orin HD patients and has become increasingly resistant to
antibiotics worldwide [2].
Elevated Methicillin-resistant S. aureus (MRSA) coloni-
zation rates are well recognized in long-term HD patients
and are associated with a high risk of blood stream infec-
tions (BSI) [3,4]. Particularly vascular catheter access rep-
resents a primary risk for BSI in HD patients [5].
Colonization of S. aureus in the anterior nares hazards
patients for subsequent infection of endogenous origin
[6]. HD patients at risk for nasal MRSA carriage are par-
ticularly those with higher age (≥75 years), prolonged
hospitalization, a history of repeated antibiotic adminis-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[7]. Recently Lai and colleagues demonstrated an asso-
ciation between nasal MRSA carriage and poor clinical
outcomes in HD outpatients [8].
Comorbidity is another known risk factor for antibiotic-
resistant bacterial infections [9]. Although the presence of
comorbid conditions can be graded using standardized
indexes, clinicians normally simply record their presence.
The Charlson Comorbidity index (CCI) was originally
designed as a measure for 1-year mortality attributable to
comorbidity in hospitalized patients and has been shown
to be a prognostic indicator in the treatment of many
types of cancer [10].
Timely recognition and isolation of HD patients co-
lonized with MRSA in combination with a stringent
decolonization regimen could be a feasible strategy to
minimize MRSA transmission rates [7,11]. MRSA colo-
nization represents an undisputed challenge for dialysis
units and few studies so far have addressed the clinical
consequences of MRSA nasal carriage in ambulatory HD
patients [7].
Confronted with the question “MRSA: total war or
tolerance?” we implemented a comprehensive infection
control practice based on the concept of “Search-Destroy-
and- Follow” in our urban outpatient dialysis centre. Our
preliminary pilot study revealed the clinical relevance of
longitudinal MRSA screening, isolating HD and eradica-
tion therapy with mupirocin ointment for effective pre-
vention of MRSA bacteremia [12].
Based on these initial findings a prospective interven-
tional surveillance study was performed over 7 years to
(i) confirm the clinical epidemiology and risk profile of
MRSA carriers, (ii) to test the effectiveness of a system-
atic MRSA screening and decolonization approach and,
most important, (iii) to characterize the outcome of
MRSA carriers requiring chronic HD in an outpatient
setting.
Methods
Study population and design
This prospective interventional cohort study was
performed in an urban non-profit dialysis-unit consis-
ting of two wards with a total of 34 beds including a se-
parated four-bed isolation room. From January 2004 to
December 2010 a total of 289 outpatients receiving
maintenance HD were enrolled. All participants gave
their informed written consent before study entry. The
analysis was carried out according to the guidelines of
the Declaration of Helsinki Principles and anonymity of
included patients was strictly preserved. The study
protocol was approved from the Ethical Comitee of the
University of Munich (Project Nr 527–12).
At study entry, patient’s clinical baseline characteristics
including major comorbid disorders (malignancy, cardiac,pulmonary and peripheral arterial occlusive disease, in-
sulin dependent diabetes mellitus IDDM, chronic HCV
infection), current immunosuppressive treatment and type
of vascular HD access were collected from medical
records by two independent investigators. Malignancy was
defined as having a history of any malignancy. Suffering
from an active malignant disease was specified as an
exclusion criterion. The Charlson Comorbidity index
(CCI) as well as the age adjusted CCI were calculated
using the ICD-10 database information [10].
Generally, longitudinal laboratory data (total blood
count, total serum protein, CRP, ferritin, iPTH and
HbA1c) were collected routinely in 6-weeks intervals or
shorter. For the present study, the most recent results at
the date the swabs were taken, were recorded and
analysed. Follow-up time was defined as the timespan
between date of first swab (study entry) and the time-
point when the patient definitely left the center (because
of death or transfer to another dialysis facility) or the
study ended (December 2010).
In brief, initial routine screening for nasal MRSA car-
riage was performed in all current patients at the time of
study initiation and in all patients that were newly ad-
mitted during the study period. Routine screening for
nasal MRSA carriage included so called “holiday dialysis
patients” (defined as patients from external dialysis faci-
lities that were treated in our unit during their stay in
Munich). Follow-up screening nasal swabs during the
study period were taken from (i) readmitted patients
after hospitalisation, (ii) patients who returned from
holiday, and (iii) patients who had assumed contact to
MRSA positive patients in the dialysis unit.
Those patients who had at least one positive nasal
MRSA culture were defined as MRSA carriers, whereas
all patients with persistent negative MRSA culture re-
sults were classified as noncarriers. The primary end
point of study was death from any cause.
Microbiology
Swabs were taken from the anterior nares of the nose by
the attending nephrologists as described [12]. Additional
swabs of throat and skin areas (forehead, ears, axillae,
hands) were taken from patients with documented nasal
MRSA carriage.
After transfer to the laboratory, swabs were placed on
mannitol salt agar and incubated at 37°C for 48 hours.
Mannitol fermenting colonies were selected and sub-
cultured to trypticase soy agar and 5% sheep blood agar
plates and incubated at 37°C. Identification of S. aureus
was based on colony morphology, DNase production
and latex agglutination as described. S. aureus isolates
were screened for methicillin resistance following the
National Committee for Clinical Laboratory standards
(NCCLS) disk-diffusion method. Overnight cultures from
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agar and a 1 μg oxacillin disk was placed on the inoculated
plate. Zone diameters were measured and recorded after
24 hour incubation at 37°C as sensitive (greater than
13 mm) or resistant (less than 10 mm).Decolonization therapy for nasal MRSA carriers and extra-
nasal MRSA colonization
Patients with nasal MRSA colonization were treated in a
separate ward (isolating HD) and received topical mu-
pirocin ointment thrice daily for five days. Additional
MRSA carriage at other sites was accessorily treated as
follows. Patients with MRSA throat colonization received
0.2% chlorhexidine mouth rinse thrice daily for five days.
Patients with positive MRSA skin swabs (forehead, ears,
axillae, hands) were treated with antiseptic octenidine
dihydrochloride containing soaps and 2% chlorhexidine
body washes once daily for five days [13,14]. An explana-
tory note detailing the specific decolonization techniques
together with the prescription for the relevant antiseptic
agent(s) (mupirocin ointment, 0.2% chlorhexidine mouth
rinse, 2% chlorhexidine body wash and antiseptic octe-
nidine dihydrochloride containing soap, respectively) was
therefore directly delivered to the patient, to family mem-
bers of carriers or, in the case of nursing home residents,
to the nursing staff respectively.
Follow-up nasal swabs were taken from nasal MRSA
carriers three to five days after completing nasal mupi-
rocin ointment. If this swab was negative for MRSA, sub-
sequent nasal swabs on the following two dialysis sessions
were performed. A series of three negative results was de-
fined as successful nasal MRSA decolonization. For con-
firmation of MRSA eradication additional nasal swabs
were taken ten days after the third negative swab, as well
as one, three and twelve months after the end of
decolonization procedures. Persistent nasal carriage was
defined by two or more consecutive positive nasal swab
cultures for MRSA.Statistical analysis
Characteristics between the groups (MRSA carriers or
noncarriers) were compared using the Kruskal-wallis test
or the Mann–Whitney U- test, as indicated. A logistic
regression model was used for analyzing associated cli-
nical factors of nasal MRSA carriage. Kaplan-Meier es-
timates were used to obtain the proportion of patients
who died of any cause during follow-up. Longitudinal
laboratory parameters were assessed with ANOVA. All
tests were two-tailed with significance defined by p
values <0.05. Statistical Package for the Social Sciences
(SPSS) for Windows Version 8.0 (SPSS Inc; Chicago, IL,
USA) and MedCalc 11.0.4 software was used for statis-
tical analysis.Results
Clinical epidemiology of nasal MRSA colonization
289 chronic dialysis patients, representing approximately
98% of all eligible outpatients that were treated during the
study period, were enrolled. A total of 1562 nasal swab
cultures were obtained. Detailed screening and outcome
results are summarized in Figure 1. The average, median,
standard deviation (SD), and range number of nasal
MRSA cultures obtained per patient for routine screening
were 5.03, 4.00, 4.50, and 1–23, respectively. 204 of the
1562 nasal swabs were performed in nasal MRSA carriers
to control efficacy of decolonization.
The screening approach identified 34 nasal MRSA car-
riers (11.7%). Prevalence of nasal MRSA carriage was 8.3%
for men and 3.4% for women. The majority of MRSA
positive patients (24/34, 70.5%) were supported by nursing
services or even were nursing home residents. Median
duration of follow-up was comparable between nasal
MRSA carriers and noncarriers (mean follow up ± SD in
months, 36 ± 23 vs. 29.5 ± 21, p = 0.11).
Concomitant extra-nasal MRSA colonization of throat
and/or skin was observed in 11 (32%) of these 34 nasal
MRSA carriers. Throat swabs were positive in four pa-
tients, swabs from skin sites were positive in five pa-
tients, and two patients tested positive in swabs from
skin and throat.
Clinical risk factors for nasal MRSA colonization and
comparison of laboratory data
Clinical characteristics that have been identified in previ-
ous studies as risk factors for MRSA colonization in HD
patients (age, IDDM, type of vascular access, cardiac and
pulmonary comorbidities, presence of peripheral arterial
occlusive disease) did not significantly differ between
nasal MRSA carriers and noncarriers (Table 1).
A total of 64 patients had a history of malignancy, 12
out of 34 nasal MRSA carriers (35.3%) and 52 out of 255
(20.4%) noncarriers, respectively. This difference was sta-
tistically significant. Chronic active HCV infection (2/34
vs. 4/255, p = 0.134) or current immunosuppressive treat-
ment (3/34 vs. 9/255, p = 0.165) did not significantly differ
between both groups.
Comparison of representative laboratory markers for
inflammation (e.g. leukocytes, CRP, ferritin) or malnu-
trition (e.g. total serum protein), recorded at the date
when the swab cultures were obtained, revealed no sig-
nificant differences between MRSA carriers and noncar-
riers (Table 1).
Age adjusted Charlson Comorbidity index and outcome
analysis
In contrast to individual comorbidities (see Table 1) appli-
cation of the age adjusted Charlson Comorbidity index
289 outpatients on chronic Hemodialysis
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Figure 1 MRSA screening and outcome results in 289 HD outpatients. All prevalent outpatients that gave informed written consent and did
not suffer from an active malignant disease (exclusion criterion) were enrolled. The 289 patients represent approximately 98% of all eligible
outpatients that were treated during the study period in our dialysis unit.
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MRSA carriers and noncarriers (median CCI [interquartile
range], 7 [2-14] vs. 9 [4-13], p < 0.001) (Figure 2). The CCI
as well as the age adjusted CCI were independent of the




Age (mean; median years) 62.0; 65.0
Insulin dependent Diabetes melitus (n,%) 95, 37.3
HD access permanent catheter (n,%) 44, 17.2
Coronary heart disease (n,%) 206, 80.8
Peripheral art. occlusive disease (n,%) 57, 22.4
Pulmonary disease (n,%) 46, 18.0
Leukocytes (k/μl) 7.70 ± 2.55
CRP (mg/dl) 1.79 ± 3.15
Ferritin (ng/ml) 500 ± 588
Total Serum Protein (g/dl) 6.66 ± 0.57
Representative clinical risk factors and comorbidities as well as typical laboratory m
between MRSA carriers and noncarriers.This analysis was performed in 31/34 MRSA posi-
tive patients and in 193/198 MRSA negative regular
outpatients, where detailed clinical charts were avai-
lable for review. Due to the lack of sufficient clinical
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Figure 2 Charlson Comorbidity index in nasal MRSA carriers and noncarriers. The age adjusted Charlson Comorbidity index showed
significant differences between 31 nasal MRSA carriers and 193 noncarriers, where sufficient clinical data were available for analysis. Box-and-whisker
plots indicating the median of the data set (middle line), the lower and upper quartiles (bottom and top of the box), and the range of values
(whiskers) are showed.
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manently treated in the dialysis facility had to be
excluded.
During follow-up 74/198 (37.4%) MRSA negative outpa-
tients and 19/34 (55.9%) MRSA positive patients died.
Causes of death are summarized in Table 2. Sepsis was de-
clared as cause of death in 26% of MRSA negative and
21% of MRSA positive patients, respectively. Kaplan-Meier
analysis showed survival differences between nasal MRSA
carriers and noncarriers with a significantly increased
probability for all cause mortality in nasal MRSA carriers
(Figure 3).Table 2 Causes of death in MRSA carriers and noncarriers











Cardiovascular disease (n;%) 20; 27 4; 21 0.154
Respiratory disease (n;%) 4; 9 5; 27 0.354
Sepsis (n;%) 19; 26 4; 21 0.162
Cerebrovascular disease (n;%) 6; 8 0; 0 0.141
Cancer (n;%) 5; 7 1; 5 0.180
Bleeding (n;%) 3; 4 1; 5 0.197
Not specified (n;%) 14; 19 4; 21 0.205
Absolute patient numbers (n) and percentages are depicted. Differences
between both groups with regard to causes of death were not significant.Detailed analysis of decolonization success and outcome
in nasal MRSA carriers
For a further detailed analysis we compared the 34
MRSA positive patients with regard to (i) effective or
failed persistent nasal MRSA decolonization and (ii) out-
come (Table 3).
(i) Repeated follow-up swabs demonstrated that our
decolonization strategy with mupirocin ointment was
effective for persistent eradication of nasal MRSA coloni-
zation in 26/34 (76.5%) patients, but failed in 8 patients. A
significant longitudinal increase in CRP levels was obvious
for patients with failure of the decolonization strategy.
The age adjusted CCI did not significantly differ between
both groups.
(ii) During follow-up 12/26 (46.1%) patients died after
successful MRSA decolonization. MRSA carriers with
failure of the MRSA eradication approach had an ex-
tremely poor prognosis with an increased all-cause
mortality (87.5%). Kaplan-Meier analysis for both
groups is summarized in Figure 4. A higher age ad-
justed CCI (median CCI [interquartile range], 9.8
[8-12] vs. 7.1 [3-12], p < 0.006) was significantly asso-
ciated with death in MRSA carriers. MRSA positive
patients who died during follow-up, showed a longitu-
dinal moderate but not significant increase of inflam-
mation markers (CRP and leukocytes) and a decline in
Hb values.























Figure 3 Kaplan-Meier analysis in nasal MRSA carriers and noncarriers. Kaplan-Meier analysis showed significant survival differences
between 34 nasal MRSA carriers and 198 noncarriers for all cause mortality. Of note, differences between both groups do not appear until after
several years of follow-up.
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skin) had no significant impact on nasal decolonization
success or survival of nasal MRSA carriers.
Discussion
Methicillin-resistant Staphylococcus aureus (MRSA) re-
mains a pathogen of crucial public health importance,
although MRSA colonization and bacteremia rates in pa-
tients requiring long term dialysis have been observed to
be decreasing in the United Kingdom [15]. Our pro-
spective investigation identified 34 (11.7%) nasal MRSA
carriers in a cohort of 289 HD outpatients of an urban
dialysis-unit. This prevalence rate is in accordance with
results of a prior pilot study [12] and in line with data
from other European surveys [16,17], even though
prevalence varies due to differences in populations and
geographic areas studied, as well as due to different sen-
sitivity of diagnostic procedures [18].
Higher age and prior hospitalization are the most
acknowledged risk factors for MRSA colonization in
patients requiring chronic HD [17,19]. Frequently notedTable 3 Comparison of 34 MRSA positive patients with regard




CRP (mg/dl) - 0.53 5.77
Hb (g/dl) 0.53 2.30
Leukocytes (k/μl) - 0.39 2.43
Basal CCI age adjusted 8.40 9.80
Additional Extra-nasal MRSA (n;%) 8; 31 3; 38
Longitudinal laboratory differences (CRP, Hb and leukocyte count), the age adjusted
baseline are summarized.other risk factors are a permanent tunneled cuffed dialy-
sis catheter, chronic obstructive lung disease, congestive
heart failure, or a sepsis history [17-21]. In addition, pro-
tein malnutrition (i.e. low serum albumin) may increase
the patients` susceptibility to MRSA colonization [19].
In our cohort neither often-quoted single risk factors
for nasal MRSA colonization such as age, type of vascu-
lar access, comorbid disorders other than a history of
malignancy, nor markers of inflammation or malnutri-
tion had the statistical power to discriminate between
MRSA carriers and noncarriers. However, an increased
age adjusted CCI was an independent predictor for nasal
MRSA colonization. These findings support the hypo-
thesis that not individual comorbidities or laboratory
markers but rather an aggregate measure of a person’s
risk due to comorbid conditions characterizing an im-
paired general state of health could serve as a significant
predictor for MRSA colonization in HD outpatients.
Early systematic screening of all patients entering the
dialysis unit combined with the option of decolonizing











0.004 - 0.15 1.42 n.s.
n.s. 0.67 −0.57 n.s.
n.s. 0.43 0.16 n.s.
n.s. 7.10 9.80 0.006
n.s. 5; 33 6; 31 n.s.
CCI and results of additional extra-nasal swabs (throat and skin) for MRSA at
Kaplan Meier 
























Figure 4 Survival differences between patients with successful MRSA decolonization and persistent nasal MRSA carriers. Kaplan-Meier
analysis showed significant survival differences between patients with successful MRSA decolonization and persistent MRSA carriers with failure of
this approach. Of note, differences between both groups do not appear until after several years of follow-up.
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carriage has generally been difficult, and currently the
routine use of decolonization for non-surgical patients
including HD patients with nasal MRSA colonization, is
not supported by data [23,24]. Mupirocin has been used
as a topical antibiotic applied to the nares and tunnel
exit sites of venous catheters HD patients to reduce S.
aureus colonization, but long-term success of this strat-
egy is unclear. Here mupirocin ointment was able to
eradicate nasal MRSA colonization in approximately
75% of carriers, documenting a significant benefit of this
strategy in an outpatient dialysis centre. Concomitant
extra-nasal MRSA colonization in nasal MRSA carriers
had no influence on nasal decolonization failure or out-
come. Due to the small sample size and the low prevalence
of extra-nasal MRSA colonization, the impact of the
applied extra-nasal decolonization approaches (0.2% chlor-
hexidine mouth rinse for throat decolonization or octeni-
dine dihydrochloride containing antiseptic soaps and 2%
chlorhexidine body washes for skin decolonization) re-
mains unclear. Of note, the important value of extra-nasal
testing for MRSA, particularly when combined with
decolonization, was unknown at the time of study initi-
ation [25].
In general, subjects with a high burden of comorbid
disorders are more susceptible to antibiotic-resistant
bacteria than the general population, although the dis-
tribution and magnitude of comorbid diseases known
as risk factors for acquiring MRSA and Methicillin-
sensitive S. aureus (MSSA) were comparable in a pooled
analysis of community- and hospital-onset cases [26].
Various reports described a robust correlation of CCI
scores and MRSA infection with consecutive bacteremia
in different cohorts [27,28]. In contrast, data evaluatingthe association between CCI score and nasal MRSA car-
riage are scarce, and only a single report in long-term-care
facility residents identified a high CCI as a significant risk
factor for nasal colonization [29].
The incidence of invasive MRSA infections is esti-
mated 100 times higher among dialysis patients than in
the general population (45 vs. 0.4 per 1000 patients)
[30], and a robust association of MRSA BSI with worse
outcome is established in hospitalized patients. Also
MRSA colonization is associated with subsequent MRSA
infection and an increased all-cause mortality among e.g.
ICU patients [31], comparable data for HD outpatients
are lacking.
A recent report demonstrated the association between
MRSA colonization and poor clinical outcomes in HD
outpatients, with a 2.5 fold increased risk for all-cause
mortality in nasal MRSA carriers compared to noncar-
riers [8]. Here we were able to establish a direct link
between elevated age adjusted CCI, nasal MRSA colo-
nization and increased all-cause mortality in HD outpa-
tients, indicating that nasal MRSA carriage is not an
immanent predictor of death by bacterial sepsis in this
population but rather serves as a surrogate marker for
a poor general condition. This finding suggests that a
distinct combination of comorbidities could result in a
positive MRSA carriage status and a worse outcome in
nasal carriers, but additional studies are needed to con-
firm these results.
There are some limitations to our study, notably
concerning microbiological technique, decolonization
approach, and study design.
First, identification of MRSA and determination of
antibiotic susceptibilities was performed according to
local protocols as recently described [12]. We did not
Schmid et al. BMC Nephrology 2013, 14:93 Page 8 of 9
http://www.biomedcentral.com/1471-2369/14/93use commercial PCR-based methods or molecular assays
to identify MRSA carriers, even though several studies
have shown a higher sensitivity for these tests [32]. Albeit
an increased proportion of infections with CA-MRSA
strains is documented in the dialysis population [33], we
have not differentiated MRSA isolates into community-
acquired (CA-MRSA) and healthcare-associated (HA-
MRSA) strains, as currently the impact of CA-MRSA
strains on mortality in HD patients is unclear [34] and
former genetic analysis of the isolated strains did not
reveal CA-MRSA strains [12]. Furthermore, as our study
approach did neither include periodical testing for nasal
MRSA carriers nor MRSA strain typing, a definite clas-
sification of MRSA acquisition was not feasible [35].
Second, we were not able to further analyze the under-
lying reasons for failure of the decolonization approach
with mupirocin in a subset of patients, even though a
significant longitudinal increase in CRP levels, probably
indicating systemic inflammation, was obvious in this
cohort. High-level mupirocin resistance, mediated by a
plasmid-encoded mupA gene, has been associated with
decolonization failure, and increased resistance rates
have been associated with increased mupirocin use [36].
In addition, although decolonization was performed in
more than 70% of patients under surveillance of nursing
services, we cannot exclude that patients’ nonadherence
has limited the success of our approach [37].
Third, the CCI used in our risk factor analysis represents
a comorbidity index that was originally designed as a longi-
tudinal measure for mortality in hospitalized patients, but
currently no more convenient index has been developed
specifically for outcome studies in the outpatient HD
population colonized with antibiotic-resistant bacteria [38].
Finally, we used all cause mortality as primary study
endpoint, but were not able to clearly determine the rate
of MRSA BSI and infection-related deaths in our cohort,
as the results of blood cultures drawn after hospital ad-
mission were not available for a systematic analysis.
However, analyzing the causes of deaths in MRSA car-
riers and noncarriers, we found even slightly higher rates
of sepsis in MRSA negative patients, arguing against the
hypothesis that MRSA BSI represent the dominant lethal
cause in nasal MRSA carriers. In addition, particularly
the first 30 days after an infection-related hospitalization
seem to represent a high-risk period for cardiovascular
events leading to a potential bias in cause of death ana-
lysis [39].
Conclusion
In conclusion, this study demonstrates that beside well-
known predictors of outcome in HD patients, such as car-
diovascular diseases or bacterial infections, nasal MRSA
carriage with failure of mupirocin decolonization is associ-
ated with significant mortality. Based on our findings,however, it remains unclear, whether nasal MRSA colo-
nization could serve “per se” as a novel predictor of out-
come or if nasal MRSA colonization is only another
surrogate marker for increased comorbidity, as a distinct
combination of comorbidities mapped in an age-adjusted
CCI results both in a positive MRSA carriage status and a
worse outcome. Further studies have now to evaluate,
whether a revised comorbidity measure specific for resis-
tant bacteria would likely provide a better assessment of
the comorbidity-attributable risk of mortality in HD
patients with nasal MRSA colonization.
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